Previous Article | Next Article 
Infection and Immunity, October 1999, p. 5186-5191, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Complement-Dependent Accumulation and Degradation
of Platelets in the Lung and Liver Induced by Injection of
Lipopolysaccharides
Masahiko
Shibazaki,1
Yoshihiro
Kawabata,2
Takashi
Yokochi,3
Akira
Nishida,4
Haruhiko
Takada,5 and
Yasuo
Endo1,*
Departments of
Pharmacology1 and Microbiology and
Immunology,5 School of Dentistry, and
Department of Animal Science, Faculty of
Agriculture,4 Tohoku University, Sendai,
Department of Dental Radiology, Kagoshima University Dental School,
Kagoshima,2 and Department of
Microbiology and Immunology, Aichi Medical University,
Nagakute,3 Japan
Received 9 March 1999/Returned for modification 26 April
1999/Accepted 16 July 1999
 |
ABSTRACT |
We found unique behaviors among platelets within a few minutes of
the intravenous injection of lipopolysaccharide (LPS) into mice.
Platelets accumulated primarily in the liver at lower doses of LPS, but
at higher doses they accumulated largely in the lungs. When the
platelets accumulated in these organs were degraded, there was a rapid
anaphylactoid shock. The platelet response depended on the strain of
mouse and on the source of LPS. Of various LPSs tested, the LPS from
the smooth type of Klebsiella O3 (KO3-S LPS) was the most potent at inducing the platelet response and shock. K-76
monocarboxylic acid, an inhibitor of complement C5, effectively prevented the KO3-S LPS-induced degradation (but not
accumulation) of platelets and the ensuing rapid shock in BALB/c mice.
Moreover, in DBA/2 mice (which are deficient in complement C5),
platelets accumulated in the lungs and liver in response to
KO3-S LPS but soon returned to the circulation without
degradation, and there was no rapid shock. The LPS from the rough type
of KO3 induced an accumulation of platelets in the liver
and lungs but not a degradation of platelets. On the basis of these
results and those reported by other investigators, we propose that in
the platelet response to LPS, the lectin pathway to form C3 convertase
from C4 and C2 is involved in the rapid accumulation of platelets in the liver and lungs and that the pathway from C5 to C9 is involved in
the destruction of platelets and the consequent anaphylactoid shock.
 |
INTRODUCTION |
Takada and Galanos (25)
found that an intravenous injection of a lipopolysaccharide (LPS) into
mice pretreated with a muramyl dipeptide induces rapid anaphylactoid
shock that quickly results in death. They further observed that the
induction of the shock depends both on the source of the LPS and on the
strain of the mouse (25, 26). Recently, we found that in
mice not pretreated with muramyl dipeptide, an intravenous injection of
an LPS induces a rapid and extensive accumulation of platelets
predominantly in the liver and lungs, and we suggested that the
degradation of platelets in the lungs may be an important factor in the
LPS-induced anaphylactoid shock (9, 23). Moreover, a partial
depletion of platelets prevented the induction of shock by LPS
(24).
Recently, we noticed that among the four strains of mice that showed no
anaphylactoid shock in the experiment reported by Takada et al.
(26), two (DBA/2 and AKR) are strains deficient in
complement C5 (4, 20). In the present study, we set out to
clarify the mechanisms underlying the rapid accumulation of platelets
and the ensuing anaphylactoid shock that are both induced by LPS while
paying particular attention to the possible role of complement.
 |
MATERIALS AND METHODS |
Mice.
BALB/c mice (male; 6 to 7 weeks old) were provided by
our university, and C57BL, C3H/HeN, and DBA/2 mice (male; 6 to 7 weeks old) were obtained from SLC Japan (Shizuoka, Japan). All experiments complied with the Guideline for Care and Use of Laboratory Animals in
Tohoku University.
LPS and other reagents.
LPS from Escherichia coli
O55:B5 (smooth [S] type) prepared by the trichloroacetic acid method
(1) was obtained from Difco (Detroit, Mich.). LPS from
Salmonella minnesota R 60 (rough [R] type) prepared by the
phenol-chloroform-petroleum ether method (10) and LPS from
S. minnesota S519 (S type) prepared by the phenol-water
method (29) were kindly provided by C. Galanos (Max-Planck-Institut für Immunbiologie, Freiburg, Germany). LPSs from Klebsiella O3 (KO3) strain LEN-1 (S type),
KO3 strain LEN-113 (R type), and E. coli K-12 (R
type) were prepared by the phenol-water method (29, 32). LPS
from Prevotella intermedia ATCC 25611 was prepared by the
phenol-chloroform-petroleum ether method as described previously
(14). LPS from E. coli O111:B4 (S type) and
Salmonella typhimurium (S type) prepared by the phenol-water method were purchased from Sigma Chemical Co. (St. Louis, Mo.). The
LPSs were dissolved or dispersed in sterile saline by the use of a
vortex mixer and injected intravenously (0.1 ml/10 g of body weight).
All experiments were carried out at 26 to 28°C. An anticomplement
agent, K-76 monocarboxylic acid (13), was provided by Otsuka
Pharmaceutical Co. Ltd. (Tokushima, Japan). This agent was dissolved in
saline with the addition of enough NaOH solution to bring the pH to
about 7.5.
Determination of the amount of protein in LPS preparations.
The protein was assayed with a Micro BCA protein assay reagent kit
(Pierce, Rockford, Ill.); the assay procedures were performed as
described by the manufacturer.
Estimation of platelet accumulation and degranulation.
Platelets contain a large amount of 5-hydroxytryptamine (5HT;
serotonin) in their granules, and free 5HT in blood is rapidly cleared
from the circulation (30). Therefore, as described in our
previous papers, by measuring the changes that occur in the amount of
5HT in the blood and in tissues such as lung, liver, and spleen, it is
possible to assess the translocation of platelets from the circulation
to the tissues (7-9, 19, 23, 24). 5HT in blood and tissues
was determined as described in these papers. Briefly, mice were
decapitated and blood (3 or 4 drops) was collected in preweighed test
tubes containing 3 ml of 0.4 M HClO4, 0.1% cysteine-HCl,
and 2 mM EDTA-2Na. After being weighed, the tube was cooled in an ice
bath. The lungs, livers, and spleens of the mice were rapidly removed
and kept in a jar with dry ice until use. Determination of 5HT levels
in the blood was done on the day the blood was collected, because the
5HT in blood collected in this way is unstable. 5HT levels in the
tissues were determined within 1 week of collection. After 5HT had been
separated by column chromatography, it was measured fluorometrically as
previously described (7).
Scoring of rapid shock induced by LPS.
The incidence and the
score given to the severity of the rapid shock and the subsequent
mortality were recorded within 30 min of the injection of LPS. The
scoring of the shock was as follows: 0, no symptoms of shock; 1, staggering; 2, crawling and prostration; 3, prostration and weak
convulsions; 4, prostration and strong convulsions.
Statistical analysis.
Experimental values for 5HT are given
as the mean ± standard deviation (SD). The statistical
significance of differences was assessed by using Dunnett's multiple
comparison test after analysis of variance; P values of less
than 0.05 were considered to indicate significance.
 |
RESULTS |
Induction of rapid anaphylactoid shock by LPSs in BALB/c mice.
The abilities of LPSs from various sources to induce rapid shock in
BALB/c mice are shown in Table 1.
KO3-S LPS was the most potent of the LPSs tested. This LPS
was lethal at 0.5 mg/kg. In contrast, KO3-R LPS did not
produce rapid shock even at 8 mg/kg. E. coli O55:B5-S LPS,
too, induced rapid shock at 0.5 mg/kg, but it was not lethal. The
amounts of contaminating protein in LPS preparations used in this study
are also shown in Table 1. We cannot explain the action of
KO3-S LPS by its contaminating protein, because
KO3-R LPS, with a dose 16 times or more that of
KO3-S LPS, was entirely inactive at inducing rapid shock.
Dependence of LPS-induced rapid shock on the strain of mice.
As shown in Table 2, KO3-S LPS
induced rapid shock in both BALB/c and C57BL/6 mice. E. coli
O55:B5-S LPS induced rapid shock only in BALB/c mice. In contrast,
P. intermedia LPS induced rapid shock in BALB/c, C57BL/6,
and C3H/HeN mice. Interestingly, P. intermedia LPS induced
shock most strongly in C3H/HeN mice, although C3H/HeN mice proved to be
resistant to the other two LPSs. None of the LPSs produced rapid shock
in DBA/2 mice, which are complement C5 deficient.
Time course of 5HT and platelet responses to the LPSs from S and R
types of KO3.
As shown in Fig.
1, KO3-S LPS at 2 mg/kg
induced marked and rapid changes in 5HT in the blood, lungs, and liver
such that 5HT disappeared almost completely from the circulation within 4 min of the injection of KO3-S LPS and 5HT accumulated in
the lungs. The amounts of 5HT accumulated in the lungs and liver at 4 min corresponded to 70 to 80 and 10 to 20% of the 5HT lost from the
blood, respectively (calculated as described in our previous papers
[9, 23]). The elevated level of 5HT in the lungs and liver had declined at 8 min without a recovery in the 5HT level in the
blood. At this dose of KO3-S LPS, severe shock occurred at 4 to 8 min and most mice had died within 20 min of the injection. We have
previously shown by electron microscopy that in such shocked mice there
is a severe degradation of platelets in the lungs (9, 23).
By comparison with the response to KO3-S LPS, the changes in
5HT in the blood and lungs induced by KO3-R LPS were mild, and the elevated 5HT levels in the lungs and liver declined in parallel
with the recovery of the decreased 5HT level in the blood. With
KO3-R LPS, the decreased 5HT level in the blood returned to
almost exactly its initial value, indicating that there was no
significant degradation of platelets.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Time course of changes in 5HT and platelet levels
induced by the LPSs of KO3-S and KO3-R in BALB/c
mice. After injection of each LPS at a dose of 2 mg/kg, blood and
tissues were taken at the indicated times. Each value is the mean ± SD from four mice. *, P <0.01 versus the
KO3-R group.
|
|
Dose dependence of the 5HT and platelet responses to
KO3-S LPS.
At lower doses of KO3-S LPS, 5HT
and platelets accumulated predominantly in the liver (Fig.
2). At 20 µg of this LPS/kg the accumulation in the liver reached a maximum. At this dose, there was no
increase in 5HT or platelets in the lungs. At higher doses of this LPS,
large amounts of 5HT and platelets accumulated, predominantly in the
lungs. In contrast, the 5HT level in the liver decreased at higher
doses, suggesting a degradation of platelets (Fig. 2).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Dose dependence of 5HT and platelet responses to
KO3-S LPS in BALB/c mice. The indicated doses of LPS were
injected into mice, and blood and tissues were taken 4 min after the
injection. Each value is the mean ± SD from four mice. *,
P <0.01 versus dose 0.
|
|
Effect of a C5 inhibitor on 5HT and platelets and on the rapid
shock induced by KO3-S LPS in BALB/c mice.
Hong et al.
(13) have reported that K-76 inhibits the activity of C
mainly at the C5 step, although at high concentrations it also causes
some inhibition of other steps. They also suggested that this agent
combines specifically with free C5 molecules and forms an inactive
complex or it causes the irreversible structural alteration of C5. An
intraperitoneal injection of K-76 1 h before injection of a lethal
dose of KO3-S LPS (1 mg/kg) largely prevented the
degradation of platelets in the lungs and liver (i.e., most of the
platelets were returned to the circulation without degradation) (Fig.
3). In this experiment, rapid shock was
largely prevented: its incidence, severity score, and lethality were 2 of 4, 0 to 1, and 0 of 4, respectively, compared to 4 of 4, 4, and 4 of
4 in the absence of K-76 (Table 1).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of K-76, an inhibitor of complement C5, on 5HT
and platelet responses to KO3-S LPS in BALB/c mice. LPS (1 mg/kg) was injected 1 h after an intraperitoneal injection of K-76
(100 mg/kg). Blood and tissues were taken 5 and 15 min after the
injection of the LPS. K-76 itself did not alter the levels of 5HT (data
not shown). Each value is the mean ± SD from four mice.
|
|
Effects of KO3-S LPS in DBA/2 mice.
Figure
4 shows the effect of KO3-S
LPS at 2 mg/kg in DBA/2 mice. In BALB/c mice, this dose is lethal and
induces a severe accumulation and degradation of platelets (Fig. 1).
However, in DBA/2 mice, the decreased level of 5HT in the blood and the
increased level in the lungs soon returned to almost exactly their
initial levels (Fig. 4), a pattern very similar to that induced by
KO3-R LPS in BALB/c mice (Fig. 1), indicating that there was
no degradation of platelets. Indeed, in this experiment,
KO3-S LPS did not produce rapid shock. Interestingly, a
marked accumulation of 5HT and platelets in the liver, as seen in
BALB/c mice at lower doses of KO3-S LPS (Fig. 2), occurred
in DBA/2 mice, too (Fig. 5). However, in
DBA/2 mice there was no decrease in the elevated level of hepatic 5HT at higher doses, indicating that there was no degradation of platelets. As in our previous studies, a similar accumulation of 5HT and platelets
in the liver at lower doses of the LPSs from E. coli and
P. intermedia was shown in BALB/c and C3H/HeN mice (9, 23).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
5HT and platelet responses to KO3-S LPS in
DBA/2 mice. Blood and tissues were taken at the indicated times after
the injection of LPS (2 mg/kg). Each value is the mean ± SD from
four mice. *, P <0.01 versus time 0.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Dose dependence of 5HT and platelet responses to
KO3-S LPS in DBA/2 mice. The indicated doses of LPS were
injected into mice, and blood and tissues were taken 4 min after the
injection. Each value is the mean ± SD from four mice. It should
be noted that the 5HT and platelet responses in the liver reached their
maximum at 0.1 mg/kg and, at this dose, there was no response in the
lungs. *, P <0.01 versus dose 0.
|
|
Accumulation of 5HT and platelets in the spleen.
Instead of a
rapid elevation of the type that was seen in the lungs and liver
following injection of either one of the KO3 LPSs in both
BALB/c and DNA/2 mice, the spleen showed a more delayed elevation of
5HT (Fig. 1, 3, and 4). In fact, the level in the spleen was rising
while the levels in the lungs and liver were falling. A similar
phenomenon has been observed in BALB/c mice given E. coli
O55:B5-S LPS (see Fig. 1 in reference 23) and in
C3H/HeN mice given P. intermedia LPS (see Fig. 1 in
reference 9). These results suggest that some of the
platelets returned to the circulation from the lungs and liver may have
been taken up by the spleen.
 |
DISCUSSION |
Our recent (9, 23) and present experiments show that
intravenous injection of LPS into mice induces a rapid response in the
platelets. This response has the following unique characteristics. (i)
Platelets accumulate primarily in the liver at lower doses of LPS, but
at higher doses they accumulate largely in the lungs. (ii) The
accumulation of platelets occurs within a few minutes of the injection
of LPS. The platelet response depends on both (iii) the strain of mouse
studied and (iv) the source or preparation of the LPS (and possibly on
the structure of the LPS). (v) The platelets accumulated in the liver
and lungs soon return to the circulation or are degraded, and the
complement system seems to be involved in this degradation. (vi) The
degradation of platelets in the lungs and liver, provided it is of
sufficient extent, induces a rapid anaphylactoid shock. We discuss
these points in the following paragraphs.
Dependence on the strain of mice.
At present, we cannot
explain why C3H/HeN mice are resistant to KO3-S LPS and
E. coli O55:B5-S LPS but sensitive to P. intermedia LPS and why only BALB/c mice are sensitive to E. coli O55:B55:B5-S LPS. In the present study, therefore, we decided
to use BALB/c mice and LPSs from KO3, because BALB/c mice
responded to all the LPSs mentioned above (Table 2) and
KO3-S LPS was the most potent at inducing rapid shock in
this strain of mice (Table 1).
Dependence on the structure of LPS.
In typical gram-negative
bacteria, wild-type strains form S-type colonies. The polysaccharide
region of the LPS of S-type bacteria is made up of an O antigen region
(built from repeating units of three to eight sugars) and a core
region. Mutant bacteria lacking the O antigen region form R-type
colonies. The present results obtained with the LPSs from the S and R
types of both KO3 and S. minnesota (Table 1)
suggest that the abilities of these LPSs to induce the platelet
response depend on the structure of the polysaccharide region,
especially on the presence or absence of the O antigen moiety. However,
it is possible that the structures of other regions may also contribute
to the activity, because E. coli K-12-R LPS was more potent
than E. coli O111-B4-S LPS (Table 1).
Return of platelets from lungs and liver to blood.
The amount
of 5HT in the lungs and liver is determined by the number of platelets
and the extent of their degradation. KO3-R LPS injected into
BALB/c mice (Fig. 1) and KO3-S LPS injected into DBA/2 mice
(Fig. 4) induced only a transient decrease in 5HT in the blood, and the
elevated 5HT levels in the lungs and liver declined in parallel with
the recovery of the decreased 5HT level in the blood. These results
indicate that the accumulation of platelets in these organs does not
necessarily lead to their degradation and that when they are not
degraded, they are returned to the circulation.
Degradation of platelets and shock.
In all the experiments in
the present study, there was a close relationship between the
degradation of platelets and the production of shock. When the
decreased level of 5HT and platelets in the blood returned roughly to
its initial level within the study period, shock was not produced.
These results indicate that it is the degradation of platelets in the
lungs and liver that leads to the rapid shock and that accumulation of
platelets in these organs (without degradation) does not itself induce shock.
Rapidity of response.
Many actions of LPS are thought to be
mediated through the production of cytokines. However, we suspect that
a substantial production of cytokines could not be produced within the
space of a few minutes after the injection of LPS. On this basis, it is
unlikely that cytokines are responsible for the rapid accumulation and
degradation of platelets induced by LPS.
Degradation of platelets in the lungs and liver and possible
involvement of the complement system.
In our previous studies of
BALB/c and C3H/HeN mice (9, 23), we showed by electron
microscopy that there is a degradation of the platelets that accumulate
in the lungs following LPS injection. DBA/2 mice have been shown to be
deficient in complement C5 (4, 20). In this strain of mice,
the response of 5HT and platelets to KO3-S LPS (Fig. 4) was
similar in extent to the response to KO3-R LPS in BALB/c
mice (Fig. 1), and the decreased level of 5HT in the blood soon
returned to its initial level. Moreover, K-76COOH, a C5 inhibitor
(13), largely prevented both the LPS-induced degradation of
platelets (Fig. 3) and the rapid shock in BALB/c mice. LPSs possessing
a mannose homopolymer in the O antigen polysaccharide region (for
example, KO3-S LPS) have been shown to activate the complement system much more strongly than LPSs possessing other polysaccharides (15, 21, 31). In our study, KO3-R
LPS, which lacks a mannose homopolymer, induced neither a significant
degradation of platelets nor rapid shock (Fig. 1 and Table 1). Using
human serum, Paeng et al. (21) compared the abilities of
various LPSs to activate complement in vitro, and showed that the order
of potencies was as follows: KO3 LEN 1 > E. coli K-12 > E. coli O111. This order is
consistent with their relative abilities to induce shock (Table 1).
Taking these results together, we conclude that the complement system
is involved in the degradation of the platelets that accumulate in the
lungs and liver under the influence of LPS.
Selective accumulation of platelets in the liver and lungs,
depending on the dose of LPS.
KO3-S LPS strongly binds
to a mannose-binding protein (MBP) (15). MBP is related
structurally and functionally to the first component of the classical
complement pathway, C1q (12, 18, 27). MBP is believed to
circulate in a complexed form with a proteinase (called MBP-associated
serine proteinase, MASP) corresponding to C1r and C1s. MBPs have a
collagen-like domain and a lectin domain. The collagen-like domain is
involved in the activation of complements, and the lectin domain is the
binding site for polysaccharides or LPS. In the classical pathway of
the complement system, the antigen-antibody-C1 complex activates C4 and
C2 to form C3 convertase (the assembly of the activated C4 and C2). The
LPS-MBP-MASP complex can also activate C4 and C2, and this pathway is
now called the lectin pathway (12, 18, 26). The receptors
for MBP, which are identical to those for C1q, are present on many cell
types, including platelets, endothelial cells, most leukocytes,
fibroblasts, and specialized epithelial cells (12). Therefore, it seems likely that MBP might be involved in the
KO3-S LPS-induced accumulation and degradation of platelets
that occurs in the liver and lungs. The different dose-dependent
response of platelets seen in the liver and lungs might be consistent
with the presence of receptors with different affinities for the
LPS-MBP-MASP complexes.
Comparison with platelet responses to LPS in other species.
Rapid falls in platelet counts and their partial or complete recovery
to initial levels also occur in other species given intravenous
injections of endotoxin. As early as 1960 and 1961, Davis et al.
(5, 6) found that simultaneously with the rapid fall in
platelets in rabbits or dogs there is an equally rapid rise in the
plasma 5HT level. Later (1972 to 1974), the rapid platelet fall was
shown to depend on the complement system in cats (17),
rabbits (2), guinea pigs (16), and dogs
(3). In C3-C9-depleted rabbits and guinea pigs (treated with
cobra venom factor) and in C4-deficient guinea pigs, the rapid drop in
platelets was not observed (2, 16).
Hypothesis for the mechanisms underlying the platelet response to
LPS.
Although the studies by other investigators mentioned above
did not examine the accumulation of platelets, their results, taken
together with our present results, support the idea that the pathway to
form C3 convertase from C4 and C2, in which C4a and C3a are also
produced, is involved in the LPS-induced rapid accumulation of
platelets in the lungs and liver and that the pathway from C5 to C9, in
which C5a and a complex of C5-C9 (called the membrane-attack complex)
are formed, is involved in the destruction of platelets in these
organs. Our tentative hypothesis is summarized in Fig.
6.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Hypothetical pathway for the LPS-induced accumulation
and degradation of platelets in the lungs and liver. In this tentative
scheme, LPS is assumed to bind to MBP-MASP complex and a consequent
complex stimulates MBP receptors on platelets and vascular endothelial
(ET) cells in the liver and lungs. The LPS-MBP-MASP complex also
activates the complement system. The pathway to form C3 convertase from
C4 and C2 may be responsible for the accumulation of platelets in the
liver and lungs. The pathway from C5 to C9 may be involved in the
destruction of platelets, and the O antigen polysaccharide region of
KO3-S LPS may be important in this step. The degradation of
platelets in the liver and lungs and the release of their contents,
including serotonin (5HT), lead rapidly to shock. When the complement
system is not activated, or if its activation is insufficient, the
platelets accumulated in the lungs and liver return to the circulation
without degradation or with only slight damage. The platelets that
suffer slight damage may be removed from the circulation by the
spleen.
|
|
It is of interest that
KO3-S LPS is a very potent inducer of
the platelet response. To our knowledge, it is the most potent
LPS at
inducing lethal shock. This finding, together with those
described
above, might provide a clue leading to the clarification
of the
mechanism underlying the pathogenic activities of
Klebsiella,
especially of
Klebsiella pneumoniae,
and thus to a better understanding
of the origins and development of
pulmonary
diseases.
It has been shown that CD14 acts as a receptor that binds LPS,
triggering inflammatory responses, such as the production of
cytokines
(
28). CD14-deficient mice are resistant to endotoxin
shock
(
11). However, as described above, it is unlikely that
cytokines are responsible for the rapid response of platelets
to LPS,
and it is not known that CD14-mediated actions of LPS
are markedly
dependent on the strain of mice. Moreover, as shown
by Takada et al.
(
26),
P. intermedia LPS can induce anaphylactoid
shock even in LPS-resistant C3H/HeJ mice, which were recently
shown to
carry a mutation in the Toll-like receptor-4 gene, leading
to defective
LPS signaling (
22). Therefore, it seems unlikely
that CD14
is required for anaphylactoid
shock.
Finally, although the primary role of platelets is believed to be in
hemostasis, our findings might suggest a new role of
platelets in
innate immunity: platelets, without the help of cytokines,
may have a
role in preventing the entry of bacteria from the circulation
into
extravascular tissues in the liver and lungs. However, we
still cannot
explain (i) why
KO3-R LPS induces platelet accumulation
but
not degradation (i.e., whether MBP is involved in the action
of this
LPS), (ii) why platelets accumulate selectively in the
liver or lungs,
depending on the dose of LPS, or (iii) why the
platelet response to LPS
depends on the strain of
mice.
 |
ACKNOWLEDGMENT |
This work was supported in part by a grant for scientific
research from the Ministry of Education of Japan (no. 10877302).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology, School of Dentistry, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980, Japan. Fax: 81-22-717-8313.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Boivin, A.,
I. Mesrobeanu, and L. Mesrobeanu.
1933.
Technique pour la préparation des polysaccharide microbiens spécifiques.
C. R. Soc. Biol.
113:490-492.
|
| 2.
|
Brown, D. L., and P. J. Lachmann.
1973.
The behaviour of complement and platelets in lethal endotoxin shock in rabbits.
Int. Arch. Allergy Appl. Immunol.
45:193-205[Medline].
|
| 3.
|
Carner, R.,
B. V. Chater, and D. L. Brown.
1974.
The role of complement in endotoxin shock and disseminated intravascular coagulation: experimental observations in the dog.
Br. J. Haematol.
28:393-401[Medline].
|
| 4.
|
Cinader, B.,
S. Dubiski, and A. C. Wardlaw.
1964.
Distribution, inheritance, and properties of an antigen, MuB1, and its relation to hemolytic complement.
J. Exp. Med.
120:897-924[Abstract].
|
| 5.
|
Davis, P. B.,
W. R. Meeker, Jr., and W. L. Bailey.
1961.
Serotonin release by bacterial endotoxin.
Proc. Soc. Exp. Biol. Med.
108:774-776.
|
| 6.
|
Davis, P. B.,
W. R. Meeker, Jr., and D. G. McQuarrie.
1960.
Immediate effects of intravenous endotoxin on serotonin concentrations and blood platelets.
Circ. Res.
8:234-239[Abstract/Free Full Text].
|
| 7.
|
Endo, Y., and M. Nakamura.
1992.
The effect of lipopolysaccharide, interleukin-1 and tumor necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse.
Br. J. Pharmacol.
105:613-619[Medline].
|
| 8.
|
Endo, Y., and M. Nakamura.
1993.
Active translocation of platelets into sinusoidal and Disse spaces in the liver in response to lipopolysaccharide, interleukin-1 and tumor necrosis factor.
Gen. Pharmacol.
24:1039-1053[Medline].
|
| 9.
|
Endo, Y.,
M. Shibazaki,
M. Nakamura, and H. Takada.
1997.
Contrasting effects of lipopolysaccharides (endotoxins) from oral black-pigmented bacteria and Enterobacteriaceae on platelets, a major source of serotonin, and on histamine-forming enzyme in mice.
J. Infect. Dis.
175:1404-1412[Medline].
|
| 10.
|
Galanos, C.,
O. Lüderitz, and O. Westphal.
1969.
A new method for the extraction of R lipopolysaccharides.
Eur. J. Biochem.
9:245-249[Medline].
|
| 11.
|
Haziot, A.,
E. Ferrero,
F. Köntgen,
N. Hijiya,
S. Yamamoto,
J. Silver,
C. L. Stewart, and S. M. Goyert.
1996.
Resistance to endotoxin-shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice.
Immunity
4:407-414[Medline].
|
| 12.
|
Holmskov, U.,
R. Malhotra,
R. B. Sim, and J. C. Jensenius.
1994.
Collectins: collagenous C type lectins of innate immune defence system.
Immunol. Today
15:67-74[Medline].
|
| 13.
|
Hong, K.,
T. Kinoshita,
W. Miyazaki,
T. Izawa, and K. Inoue.
1979.
An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade.
J. Immunol.
122:2418-2423[Abstract/Free Full Text].
|
| 14.
|
Iki, K.,
K. Kawahara,
S. Sawamura,
R. Arakaki,
T. Sakuta,
A. Sugiyama,
H. Tamura,
T. Sueda,
S. Hamada, and H. Takada.
1997.
A novel component different from endotoxin extracted from Prevotella intermedia ATCC 25611 activates lymphoid cells from C3H/HeJ mice and gingival fibroblasts from humans.
Infect. Immun.
65:4531-4538[Abstract].
|
| 15.
|
Jiang, G. Z.,
T. Sugiyama,
Y. Kato,
N. Koide, and T. Yokochi.
1995.
Binding of mannose-binding protein to Klebsiella 03 lipopolysaccharide possessing the mannose homopolysaccharide as the O-specific polysaccharide and its relation to complement activation.
Infect. Immun.
63:2537-2540[Abstract].
|
| 16.
|
Kane, M. A.,
J. E. May, and M. M. Frank.
1973.
Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide: effect on platelets and blood coagulation.
J. Clin. Investig.
52:370-376.
|
| 17.
|
Kitzmiller, J. L.,
W. E. Lucas, and P. F. Yelenosky.
1972.
The role of complement in feline endotoxin shock.
Am. J. Obstet. Gynecol.
112:414-421[Medline].
|
| 18.
|
Malhotra, R.,
J. Lu,
U. Holmskov, and R. B. Sim.
1994.
Collectins, collectin receptors and the lectin pathway of complement activation.
Clin. Exp. Immunol.
97(Suppl. 2):4-9.
|
| 19.
|
Nakamura, M.,
M. Shibazaki,
Y. Nitta, and Y. Endo.
1998.
Translocation of platelets into Disse spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-1 and tumor necrosis factor: the role of Kupffer cells.
J. Hepatol.
28:991-999[Medline].
|
| 20.
|
Ooi, M., and H. R. Colten.
1979.
Genetic defect in secretion of complement C5 in mice.
Nature
282:207-208[Medline].
|
| 21.
|
Paeng, N.,
N. Kido,
G. Schmidt,
T. Sugiyama,
Y. Kato,
N. Koide, and T. Yokochi.
1996.
Augmented immunological activities of recombinant lipopolysaccharide possessing the mannose homopolymer as the O-specific polysaccharide.
Infect. Immun.
64:305-309[Abstract].
|
| 22.
|
Poltorak, A.,
X. He,
I. Smirnova,
M.-Y. Liu,
C. Van Huffel,
X. Du,
D. Birdwell,
E. Alejos,
M. Silva,
C. Galanos,
M. Freudenberg,
P. Ricciardi-Castagnoli,
B. Layton, and B. Beutler.
1998.
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutation in Tlr4 gene.
Science
282:2085-2088[Abstract/Free Full Text].
|
| 23.
|
Shibazaki, M.,
M. Nakamura, and Y. Endo.
1996.
Biphasic, organ-specific, and strain-specific accumulation of platelets induced in mice by a lipopolysaccharide from Escherichia coli and its possible involvement in shock.
Infect. Immun.
64:5290-5294[Abstract].
|
| 24.
|
Shibazaki, M.,
M. Nakamura,
Y. Nitta, and Y. Endo.
1998.
Displacement of platelets from blood to spleen following intravenous injection of liposomes encapsulating dichloromethylene bisphosphonate.
Immunopharmacology
39:1-7[Medline].
|
| 25.
|
Takada, H., and C. Galanos.
1987.
Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice.
Infect. Immun.
55:409-413[Abstract/Free Full Text].
|
| 26.
|
Takada, H.,
H. Hirai,
T. Fujiwara,
T. Koga,
T. Ogawa, and H. Hamada.
1990.
Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide.
J. Infect. Dis.
162:428-434[Medline].
|
| 27.
|
Turner, M. W.
1994.
Mannose binding protein.
Biochem. Soc. Trans.
22:1993-1995.
|
| 28.
|
Urevitch, R. J., and P. S. Tobias.
1995.
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin.
Annu. Rev. Immunol.
13:437-457[Medline].
|
| 29.
|
Westphal, O., and K. Jann.
1965.
Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure.
Methods Carbohydr. Chem.
5:83-91.
|
| 30.
|
Wiggins, R. C.,
A. Glatfelter,
A. M. Campbell,
R. G. Kunkel, and R. J. Ulevitch.
1985.
Acute hypotension due to platelet serotonin-induced chemoreflexes after intravenous injection of dextran sulfate in the rabbit.
Circ. Res.
57:262-277[Abstract/Free Full Text].
|
| 31.
|
Yokochi, T.,
Y. Inoue,
T. Kimura, and N. Kato.
1990.
Strong interaction of lipopolysaccharides possessing the mannose homopolysaccharides with complement and its relation to adjuvant action.
J. Immunol.
144:3106-3110[Abstract].
|
| 32.
|
Yokochi, T.,
Y. Inoue,
J. Yokoo,
Y. Kimura, and N. Kato.
1989.
Retention of bacterial lipopolysaccharide at the site of subcutaneous injection.
Infect. Immun.
57:1786-1791[Abstract/Free Full Text].
|
Infection and Immunity, October 1999, p. 5186-5191, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhang, G., Han, J., Welch, E. J., Ye, R. D., Voyno-Yasenetskaya, T. A., Malik, A. B., Du, X., Li, Z.
(2009). Lipopolysaccharide Stimulates Platelet Secretion and Potentiates Platelet Aggregation via TLR4/MyD88 and the cGMP-Dependent Protein Kinase Pathway. J. Immunol.
182: 7997-8004
[Abstract]
[Full Text]
-
Wideman, R. F., Bowen, O. T., Erf, G. F.
(2009). Broiler pulmonary hypertensive responses during lipopolysaccharide-induced tolerance and cyclooxygenase inhibition. Poult. Sci.
88: 72-85
[Abstract]
[Full Text]
-
Chen, H.-W., Kuo, H.-T., Chai, C.-Y., Ou, J.-L., Yang, R.-C.
(2007). Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia. Innate Immunity
13: 15-23
[Abstract]
-
Jayachandran, M., Brunn, G. J., Karnicki, K., Miller, R. S., Owen, W. G., Miller, V. M.
(2007). In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J. Appl. Physiol.
102: 429-433
[Abstract]
[Full Text]
-
Andonegui, G., Kerfoot, S. M., McNagny, K., Ebbert, K. V. J., Patel, K. D., Kubes, P.
(2005). Platelets express functional Toll-like receptor-4. Blood
106: 2417-2423
[Abstract]
[Full Text]
-
Aird, W. C.
(2003). The Hematologic System as a Marker of Organ Dysfunction in Sepsis. Mayo Clin Proc.
78: 869-881
[Abstract]
-
Aird, W. C.
(2003). The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood
101: 3765-3777
[Abstract]
[Full Text]
-
Warkentin, T. E., Aird, W. C., Rand, J. H.
(2003). Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. ASH Education Book
2003: 497-519
[Abstract]
[Full Text]
-
Zhao, L., Ohtaki, Y., Yamaguchi, K., Matsushita, M., Fujita, T., Yokochi, T., Takada, H., Endo, Y.
(2002). LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood
100: 3233-3239
[Abstract]
[Full Text]
-
Takada, H., Yokoyama, S., Shuhua Yang,
(2002). Mini-review: Enhancement of endotoxin activity by muramyldipeptide. Innate Immunity
8: 337-342
[Abstract]
-
MONODANE, T., KAWABATA, Y., YANG, S., HASE, S., TAKADA, H.
(2001). Induction of necrosis factor-{alpha} and interleukin-6 in mice in vivo and in murine peritoneal macrophages and human whole blood cells in vitro by Micrococcus luteus teichuronic acids. J Med Microbiol
50: 4-12
[Abstract]
[Full Text]